Celcuity's breast cancer combo hits goals, teeing up FDA filing - Fierce Biotech

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for success to tee up a filing for FDA approval in the fourth quarte | A phase 3 trial of Celcuity’s breast cancer combination has hit its p…